Journal of Clinical Oncology
Articles in this Issue
Global landscape and trends of antibody-drug conjugates in oncology: A machine learning–driven decade-long informatics analysis.
e15038 Background: Antibody-Drug Conjugates (ADCs) are reshaping the treatment standard for a wide range of tumors. Howeve...
Second primary malignancies (SPM) risk after CAR T-cell therapy: A real-world analysis.
e23445 Background: Chimeric antigen receptor (CAR) T-cell therapy is an engineered T-cell therapy that offers curative pot...
Tumor treating fields in newly diagnosed glioblastoma: An updated systematic review and meta-analysis with geographic subgroup analysis.
e14087 Background: Tumor Treating Fields (TTFields) combined with temozolomide received FDA approval for newly diagnosed g...
Cognition of apalutamide + ADT treatment responders versus non-responders.
5085 Background: LIBERTAS (NCT05884398) evaluates intermittent androgen deprivation therapy (ADT) with apalutamide monothe...
Navigating the post–covalent bruton tyrosine kinase inhibitor (cBTKi) landscape in mantle cell lymphoma (MCL): Real-world insights on treatment patterns, discontinuation, and healthcare resource utilization (HCRU).
7058 Background: cBTKis have become standard therapy for relapsed/refractory MCL and are rapidly advancing to the first-li...
Prognostic impact of AXL expression in upper gastrointestinal cancer in MONSTAR-SCREEN-2: An international collaborative study between United States and Japan.
4032 Background: AXL, a receptor tyrosine kinase of the TAM family, promotes epithelial-mesenchymal transition (EMT) and t...
AQP4 and MOG as definers of distinct autoantibody signatures in immune checkpoint inhibitor–induced optic neuritis.
12128 Background: Checkpoint blockade–induced optic neuritis (CBON) is a rare but vision-threatening immune-related advers...
A national analysis of in-hospital outcomes following cytoreductive surgery with HIPEC.
e16497 Background: Cytoreductive surgery with hyperthermic intra-peritoneal chemotherapy (HIPEC) is an aggressive multi-mo...
Machine learning–optimized multi-biomarker panel for discriminating lung cancer from LDCT-positive benign pulmonary nodules.
10539 Background: Accurate discrimination between lung cancer and benign pulmonary nodules remains a critical challenge in...
Prognostic significance of imaging-detected extranodal extension (iENE) in pathological ENE-negative head and neck squamous cell carcinoma.
6079 Background: Advances in perioperative systemic therapy for head and neck squamous cell carcinoma (HNSCC) (e.g., KEYNO...
Effect of a weight loss intervention (WLI) on quality of life (QOL) and symptoms in women with breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.
12010 Background: BWEL (Alliance A011401; NCT02750826) is a Phase III trial that randomizes patients (pts) with stage II-I...
Assessing the role of oncologist type in shared decision-making for patients with metastatic breast cancer.
e13085 Background: Metastatic breast cancer (MBC) involves complex treatment plans, as patients and their oncologists must...
Perspectives of oncology professionals on cancer care for displaced populations in Africa.
e13503 Background: Over 45.9M Africans are forcibly displaced, including over 35M Internally Displaced Persons and around...
Designing a triple-negative breast cancer patient journey: A multi-stakeholder initiative to improve clinical pathways and communication in Italy.
e13507 Background: Triple negative breast cancer (TNBC) is associated with poor prognosis and complex management, requirin...
A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2– breast cancer and Oncotype recurrence score ≤ 25 (OFSET): NRG-BR009.
TPS650 Background: The TAILORx and RxPONDER trials showed that recurrence score (RS) identifies many postmenopausal pts wh...
Synergistic probiotic–chemotherapy remodeling of the intratumoral microbiome as a driver of mature tertiary lymphoid structure formation and anti-tumor immunity in colorectal cancer.
e15672 Background: Neoadjuvant chemo-immunotherapy shows promise for advanced colorectal cancer (CRC), but its efficacy is...
Genomic instability score (GIS) and real-world outcomes in patients (pts) with advanced ovarian cancer (aOC) using a U.S. health database.
e17565 Background: Identification of homologous recombination deficiency biomarkers are needed to determine which pts with...
Trial characteristics and results reporting among oncology clinical trials involving African countries.
1589 Background: Sub-Saharan Africa (SSA) faced ~801,000 new cancer cases and ~520,000 cancer deaths in 2020, with deaths...
Trajectories of cervical cancer patients through the health systems of Colombia and Guatemala
e13800 Cervical cancer (CC) is the 2nd most prevalent cancer among women from low and middle-income countries. Latin America faces the 2nd hig...
Palliative care involvement at the end of life in advanced cancer.
12033 Background: High-intensity end-of-life (EoL) care in advanced cancer is common, costly, and often misaligned with pa...
Real-world outcomes of TP53-mutated acute myeloid leukemia at a single institution.
e18543 Background: TP53-mutated acute myeloid leukemia (AML) represents a high-risk subset with poor response to conventio...
Combination of golidocitinib (a JAK1 inhibitor) with anti–PD-1 antibody to improve tumor response and patient quality of life: Preliminary results from an ongoing JACKPOT 33 study.
8555 Background: Chemo-immunotherapy remains the standard first-line treatment for advanced non-small cell lung cancer (NS...
Estimating survival in advanced cancer: A prospective single-center study on the accuracy of oncologists’ prognostic accuracy (Pre-Sur).
11133 Background: The ability to estimate survival is a cornerstone of care for patients (pts) with advanced cancer, influ...
Using organoids to predict efficacy of adjuvant treatment to improve outcome in resectable pancreatic cancer: UNITEPANC (AIO-PAK-0424), a prospective, multicenter, proof-of-concept trial of the AIO Pancreatic Cancer Group.
TPS4266 Background: Pancreatic cancer (PDAC) is a heterogeneous disease and there is a lack of predictive biomarker to gui...
Randomized phase II trial of olaparib and pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2) mutations: SWOG S2001.
4012 Background: Preclinical studies have demonstrated that PARP inhibitors modulate the immune microenvironment by increa...